Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 15/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28713485 | 0.86 | RET (0.41) | RETAKR1C3PANK3PPARGPPARD | |
| SCHEMBL28701006 | 0.86 | RET (0.44) | RETAKR1C3PANK3PPARGPPARD | |
| SCHEMBL28716591 | 0.86 | RET (0.41) | RETAKR1C3PANK3PPARGPPARD | |
| SCHEMBL29782969 | 0.86 | RET (0.41) | RETAKR1C3PANK3PPARGPPARD | |
| SCHEMBL24879320 | 0.85 | RET (0.47) | RET | |
| SCHEMBL30111209 | 0.85 | RET (0.47) | RET | |
| SCHEMBL29749393 | 0.85 | RET (0.45) | RETAKR1C3PANK3PPARGPPARD | |
| SCHEMBL26960371 | 0.85 | RET (0.45) | RETAKR1C3PANK3PPARGPPARD | |
| SCHEMBL6698881 | 0.84 | MAPT (0.53) | RETPANK3 | |
| SCHEMBL22796021 | 0.84 | CPB2 (0.42) | RETAKR1C3PANK3PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | RET 3084/4885AKR1C3 2045/4885PANK3 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.